RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE UROTHELIAL CARCINOMA

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512683-53-00

Enrollment

312

Registered

2024-04-23

Start date

2018-05-18

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-muscle invasive bladder cancer

Brief summary

Early recurrence rate of CVNMI.

Detailed description

Adverse events of the drugs administered., Demographic characteristics (age, sex)., Clinical characteristics (TNM classification, risk group, time of evolution, previous treatments received)

Interventions

DRUGCisplatino Pharmacia 1 mg/ml concentrado para solución para perfusión EFG

DRUGFarmiblastina 50 mg polvo para solución inyectable

DRUGMitomicina Accord 40 mg polvo para solución inyectable y para perfusión EFG

DRUGGemcitabina Accord 1 g Pó para solução para perfusão

DRUGDocetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión

DRUGFarmorubicina 50 mg polvo para solución inyectable y para perfusión

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Early recurrence rate of CVNMI.	—

Secondary

Measure	Time frame
Adverse events of the drugs administered., Demographic characteristics (age, sex)., Clinical characteristics (TNM classification, risk group, time of evolution, previous treatments received)	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026